BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 10381760)

  • 1. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
    Witherow LE; Houston JB
    J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.
    Carlile DJ; Zomorodi K; Houston JB
    Drug Metab Dispos; 1997 Aug; 25(8):903-11. PubMed ID: 9280396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.
    Carlile DJ; Hakooz N; Houston JB
    Drug Metab Dispos; 1999 Apr; 27(4):526-32. PubMed ID: 10101148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
    Yu A; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
    Ashforth EI; Carlile DJ; Chenery R; Houston JB
    J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism.
    Tang W; Stearns RA; Kwei GY; Iliff SA; Miller RR; Egan MA; Yu NX; Dean DC; Kumar S; Shou M; Lin JH; Baillie TA
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1068-74. PubMed ID: 10565826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
    Hayes KA; Brennan B; Chenery R; Houston JB
    Drug Metab Dispos; 1995 Mar; 23(3):349-53. PubMed ID: 7628300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
    Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
    Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
    Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
    Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.
    Carlile DJ; Stevens AJ; Ashforth EI; Waghela D; Houston JB
    Drug Metab Dispos; 1998 Mar; 26(3):216-21. PubMed ID: 9492383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
    Jaruratanasirikul S; Cooper AD; Blaschke TF
    Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
    Obach RS
    Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes.
    Sarver JG; Bachmann KA; Zhu D; Klis WA
    Drug Metab Dispos; 1998 Jan; 26(1):78-82. PubMed ID: 9443857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.
    Desta Z; Soukhova N; Morocho AM; Flockhart DA
    J Pharmacol Exp Ther; 2001 Aug; 298(2):508-20. PubMed ID: 11454912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
    Houston JB; Kenworthy KE
    Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
    Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
    Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.